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Background: As a result of the widespread resistance to chloroquine and sulphadoxine-pyrimethamine,
artemisinin-based combination therapy (ACT) (including artemether-lumefantrine and artesunate-amodiaquine) has
been recommended as a first-line anti-malarial regimen in Senegal since 2006. Intermittent preventive treatments
with anti-malarial drugs based on sulphadoxine-pyrimethamine are also given to children or pregnant women once
per month during the transmission season. Since 2006, there have been very few reports on the susceptibility of
Plasmodium falciparum to anti-malarial drugs. To estimate the prevalence of resistance to several anti-malarial drugs
since the introduction of the widespread use of ACT, the presence of molecular markers associated with resistance
to chloroquine and sulphadoxine-pyrimethamine was assessed in local isolates at the military hospital of Dakar.
Methods: The prevalence of genetic polymorphisms in genes associated with anti-malarial drug resistance, i.e., Pfcrt,
Pfdhfr, Pfdhps and Pfmdr1, and the copy number of Pfmdr1 were evaluated for a panel of 174 isolates collected from
patients recruited at the military hospital of Dakar from 14 October 2009 to 19 January 2010.
Results: The Pfcrt 76T mutation was identified in 37.2% of the samples. The Pfmdr1 86Y and 184F mutations were
found in 16.6% and 67.6% of the tested samples, respectively. Twenty-eight of the 29 isolates with the 86Y mutation
were also mutated at codon 184. Only one isolate (0.6%) had two copies of Pfmdr1. The Pfdhfr 108N/T, 51I and 59R
mutations were identified in 82.4%, 83.5% and 74.1% of the samples, respectively. The double mutant (108N and 51I)
was detected in 83.5% of the isolates, and the triple mutant (108N, 51I and 59R) was detected in 75.3%. The Pfdhps
437G, 436F/A and 613S mutations were found in 40.2%, 35.1% and 1.8% of the samples, respectively. There was no
double mutant (437G and 540E) or no quintuple mutant (Pfdhfr 108N, 51I and 59R and Pfdhps 437G and 540E). The
prevalence of the quadruple mutant (Pfdhfr 108N, 51I and 59R and Pfdhps 437G) was 36.5%.
Conclusions: Since 2004, the prevalence of chloroquine resistance had decreased. The prevalence of isolates with
high-level pyrimethamine resistance is 83.5%. The prevalence of isolates resistant to sulphadoxine is 40.2%. However,
no quintuple mutant (Pfdhfr 108N, 51I and 59R and Pfdhps 437G and 540E), which is associated with a high level of
sulphadoxine-pyrimethamine resistance, has been identified to date. The resistance to amodiaquine remains moderate.
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During the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. One strategy for reducing
malaria prevalence is the use of drugs in combination.
Drug combinations help prevent the development of
resistance to each component drug and reduce the over-
all transmission of malaria [2]. In response to increas-
ing chloroquine resistance, Senegal in 2004 switched to
sulphadoxine-pyrimethamine with amodiaquine as the
first-line therapy. In 2006, artemether-lumefantrine and
artesunate-amodiaquine were the forms of artemisinin-
based combination therapy (ACT) recommended by the
WHO as the first-line anti-malarial regimen for managing
uncomplicated malaria. Since 2006, more than 1.5 million
treatments have been administered in Senegal [3]. During
2009, 184,170 doses of ACT were dispensed in Senegal [4].
Dakar, the capital city of Senegal, has an urban popula-
tion of approximately 1.1 million and a suburban popula-
tion of 2.3 million; the city covers the majority of the Cap-
Vert Peninsula. Malaria is transmitted in Dakar and its
surrounding suburbs, with spatial heterogeneity of the
human biting rate, which ranged from 0.1 to 250 bites per
person per night during the rainy season from 2007 to
2010 [5]. Intermittent preventive treatment (IPT) with
anti-malarial drugs given to all children and pregnant
women once per month during the transmission season
can provide a high degree of protection against malaria.
Seasonal IPT with sulphadoxine-pyrimethamine and one
dose of artesunate resulted in a 90% reduction in the
incidence of clinical malaria in Senegal [6]. The combin-
ation of sulphadoxine-pyrimethamine and amodiaquine
was more effective than the combination of sulphadoxine-
pyrimethamine and artesunate or the combination of
amodiaquine and artesunate in preventing malaria [7].
During IPT with sulphadoxine-pyrimethamine and piper-
aquine, only 3.4% of the treated children developed
malaria [8].
Since the introduction of ACT and IPT trials in Senegal,
there have been very few reports on the level of resistance
of P. falciparum to anti-malarial drugs. To determine
whether parasite susceptibility has been affected by the
new anti-malarial policies, a study of molecular markers
was conducted with local isolates obtained from the mili-
tary hospital of Dakar (Hôpital Principal de Dakar). The
prevalence of genetic polymorphisms in genes associated
with anti-malarial drug resistance was evaluated. The
genes interest included P. falciparum chloroquine resist-
ance transporter (Pfcrt) for chloroquine [9], P. falciparum
dihydrofolate reductase (Pfdhfr) for pyrimethamine [10],
P. falciparum dihydropteroate synthase (Pfdhps) for sul-
phadoxine [11] and P. falciparum multidrug resistance 1
(Pfmdr1) for mefloquine resistance [12] and potentially for
quinoline resistance [13,14].The Pfcrt gene was firstly identified in 2000 [9]. So far
at least 20 mutation points were described [9,15,16], but
only one is the reference mutation, the marker of
chloroquine resistant phenotype: K76 that becomes T76
when mutated. This mutation is often associated with
other mutations in the Pfcrt gene (Cys72Ser, Met74Ile,
Asn75Glu, Ala220Ser, Gln271Glu, Asn326Ser, Ile356Thr,
Arg371Ile). The role of these mutations is not yet
defined. The odds ratio (OR) for failure associated with
K76T mutation was 2.1 (95% confidence interval: 1.5-3.0,
meta-analysis of 13 studies) for a 14-day follow-up and 7.2
(95%CI: 4.5-11.5, meta-analysis of 12 studies) for a 28-day
follow-up [17]. However, the existence of chloroquine-
susceptible strains associated with K76T mutation sug-
gests that other genes could be involved in resistance to
chloroquine.
The Ser108Asn mutation on the Pfdhfr gene is asso-
ciated with resistance to anti-folate drugs [18]. The OR
for sulphadoxine-pyrimethamine failure associated with
Ser108Asn was 3.5 (95%CI: 1.9-6.3, meta-analysis of 10
studies) for a 28-day follow-up [17]. The additional
mutations Asn51Ile, Cys59Arg or Ile164Leu increase the
level of in vitro resistance to antifolate drugs and sulpha-
doxine-pyrimethamine. The OR for codon 51 and 59
single mutants were 1.7 (95%CI: 1.0-3.0) and 1.9 (95%CI:
1.4-2.6), respectively [17]. The triple mutation (51+59+108)
increases the risk of in vivo resistance to sulphadoxine-
pyrimethamine by 4.3 (95%CI: 3.0-6.3, meta-analysis of
22 28-day studies) [17].
Sulphones (dapsone) and sulphonamides (sulphadoxine)
are inhibitors of P. falciparum DHPS [19]. The mutations
Ser436Ala, Ser436Phe, Ala437Gly and Lys540Glu are in-
volved in resistance to sulphadoxine [11]. The single mu-
tation Ala437Gly and the double mutation Ala437Gly
+Lys540Glu increase the risk of in vivo resistance to
sulphadoxine-pyrimethamine by 1.5 (95%CI: 1.0-2.4,
meta-analysis of 12 studies) and 3.9 (95%CI: 2.6-5.8, meta-
analysis of 10 studies), respectively [17].
The quintuple mutant of Pfdhfr (codons 51+59+108)
plus Pfdhps (codons 437+540) increases the risk of
in vivo resistance to sulphadoxine-pyrimethamine by 5.2
(95%CI: 3.2-8.8, meta-analysis of 3 studies) [17].
Pfmdr1, which encodes a 162 kDa protein named
P. falciparum homologue of the P-glycoprotein (Pgh1), is
located on chromosome 5. Field work has shown that the
predictive value for chloroquine resistance and point
mutations in the Pfmdr1 sequence resulting in amino acid
changes varies depending on the geographic area [20,21].
Five point mutations have been described: N86Y, Y184F,
S1034C, N1042D and D1246Y. Point mutations, most
notably N86Y, have been associated with a decrease in the
chloroquine susceptibility [22]. However, in some of these
epidemiological studies, the number of chloroquine-
susceptible samples is too limited to provide statistically
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only weak relationships are established in P. falciparum
between chloroquine resistance and mutations in Pfmdr1
[24]. However, the risk of therapeutic failure with chloro-
quine is greater for patients harbouring the N86Y muta-
tion with an OR of 2.2 (95%CI: 1.6-3.1) with a 14-day
follow-up and 1.8 (95%CI: 1.3-2.4) with a 28-day follow-up
[17]. The combination of Pfmdr1 N86Y and Pfcrt K76T
increases the risk of in vivo resistance to chloroquine by
3.9 (95%CI: 2.6-5.8, meta-analysis of 5 studies) [17].
In addition, the risk of therapeutic failure with amo-
diaquine is greater for patients harbouring the N86Y
mutation with an OR of 5.4 (95%CI: 2.6-11.2, meta-
analysis of six studies) [17]. This mutation increases the
risk of failure with amodiaquine plus sulphadoxine-
pyrimethamine by 7.9 [25].
It has been shown through heterologous expression
that Pfmdr1 mutations at codons 1034 and 1042 abolish
or reduce the level of resistance to mefloquine [26].
Moreover, transfections with a wild-type Pfmdr1 allele at
codons 1034, 1042 and 1246 confer mefloquine resist-
ance to susceptible parasites [27]. However, mutations at
codons 1034, 1042 and 1246 in P. falciparum Pfmdr1
isolates are not sufficient to explain variations in meflo-
quine susceptibility [28]. Analyses of P. falciparum iso-
lates showed an association between mutation at the
codon 86 and an increase in susceptibility to mefloquine,
halofantrine or artemisinin derivatives [29-31].
Amplification and overexpression of Pfmdr1 has been
associated with mefloquine resistance and halofantrine
decreased susceptibility in P. falciparum [32,33] Recently,
Price et al. showed that amplification of Pfmdr1 is the
main cause of resistance to mefloquine in P. falciparum
[12]; the Pfmdr1 copy number could be used as a molecu-
lar marker to monitor mefloquine drug resistance in areas
of emerging resistance [29]. The OR for mefloquine failure
in monotherapy associated with Pfmdr1 amplification is
8.6 (95%CI: 3.3-22.9) at day 28 [17]. Increased copy num-
ber from 1 to 2 is associated with a significant high risk of
clinical failures with mefloquine-artesunate (OR=2.6)
[17,34] and artemether-lumefantrine [17]. Increase of
Pfmdr1 copy is associated with in vitro reduced suscepti-
bility to artemisinin derivatives [35-37]. However, increase
of Pfmdr1 copy seems to be not associated with in vivo
prolonged clearance time [38,39].
Methods
Plasmodium falciparum isolates
In total, 188 patients (109 males and 79 females) with
malaria were recruited from 14 October 2009 to 19
January 2010 at the Hôpital Principal de Dakar. Venous
blood samples were collected in VacutainerW ACD tubes
(Becton Dickinson, Rutherford, NJ, USA) prior to patient
treatment. Parasitaemia ranged from 0.3% to 35% inmale group and from 0.01% to 10% in female group.
Informed verbal consent was obtained from patients and/
or their parents before blood collection. The study was
reviewed and approved by the ethical committee of the
Hôpital Principal de Dakar. Patients were treated by arte-
mether-lumefantrine, quinine or quinine-doxycycline.
Nucleic acid extraction
Total genomic DNA of each strain was isolated using
the QIAampW DNA Mini kit according to the manufac-
turer’s recommendations (Qiagen, Germany).
Pfcrt single-nucleotide polymorphisms (SNPs)
A 546-nucleotide fragment of the Pfcrt gene (containing
codon 76) was amplified by PCR using CRTP1-sense 5’-
CCG TTA ATA ATA AAT ACA CGC AG-3’ and CRTP1-
antisense 5’-CGG ATG TTA CAA AAC TAT AGT TAC
C-3’ primers [40]. The reaction mixture for PCR am-
plifications included 2.5 μl of genomic DNA, 2.5 μl
of 10X reaction buffer (Eurogentec), 0.5 μM of each
primer, 200 μM of a deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Euromedex,
Souffelweyersheim, France), 2.5 mM MgCl2 and 1 unit of
RedGoldStarW DNA polymerase (Eurogentec) in a final
volume of 25 μl. The thermal cycler (T3 Biometra,
Archamps, France) was programmed as follows: an initial
94°C incubation for 5 min; 40 cycles of 94°C for 20 sec,
56°C for 20 sec and 60°C for 40 sec; and a final 5-min ex-
tension step at 60°C. The PCR products were loaded on a
1.5% agarose gel containing 0.5 μg/mL ethidium bromide.
The PCR products were diluted 1:100 in distilled water,
and 2.5 μl of the final dilution was used for the second
PCR. This PCR amplified a 275 bp segment around the
mutation using a common inner primer CRTP3-sense
5’-TGA CGA GCG TTA TAG AG-3’ coupled with either
CRTP4m-antisense 5’-GTT CTT TTA GCA AAA ATT
G-3’ (detects the 76 T codon) or CRTP4w-antisense
5’-GTT CTT TTA GCA AAA ATT T-3’ (detects the 76 K
codon) [15]. The reaction mixture for the PCR ampli-
fications included 2.5 μl of diluted PCR product,
2.5 μl of 10X reaction buffer (Eurogentec), 0.5 μM of
each primer, 200 μM deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Euromedex,
Souffelweyersheim, France), 1.5 mM MgCl2 and 0.75 U of
RedGoldStarW DNA polymerase (Eurogentec) in a final
volume of 25 μl.
The PCR conditions were at 94°C for 5 min; 15 cycles at
94°C for 20 sec, 48.5°C for 20 sec and 64°C for 40 sec; and
a final 5 min extension step at 64°C. Purified genomic DNA
from P. falciparum clones 3D7 (chloroquine sensitive) and
W2 (chloroquine resistant) were used as positive controls,
and water and human DNA were used as negative controls.
The PCR products from the amplification reactions were
evaluated by electrophoresis on 2% agarose gels.
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Two primer pairs were used to amplify pfmdr1 fragments
carrying the five key codons [41]. A 590-base pair frag-
ment was amplified with the primer pair sense 5’-AGA
GAA AAA AGA TGG TAA CCT CAG-3’ and antisense
5’-ACC ACA AAC ATA AAT TAA CGG-3’ to determine
the sequences of codons 86 and 184 (MDR1-1), and a sec-
ond fragment (968 base pairs) was amplified with the pri-
mer pair sense 5’-CAG GAA GCA TTT TAT AAT ATG
CAT-3’ and antisense 5'-CGT TTA ACA TCT TCC AAT
GTT GCA-3' to determine the sequences of codons 1034,
1042, and 1246 (MDR1-2) [41]. The reaction mixture con-
sisted of approximately 2.5 μl of genomic DNA, 0.5 μM
of forward and reverse primers, 2.5 μl of 10X reaction
buffer (Eurogentec), 2.5 mM MgCl2, 200 μM deoxy-
nucleoside triphosphate mixture (dGTP, dATP, dTTP
and dCTP) (Euromedex, Souffelweyersheim, France) and
1 U of RedGoldStarW DNA polymerase (Eurogentec) in a
final volume of 25 μl. The thermal cycler (T3 Biometra)
was programmed as follows: for MDR1-1, an initial 94°C
for 5 min; 40 cycles of 94°C for 30 sec, 52°C for 30 sec and
72°C for 1 min; and a final 10-min extension step at 72°C;
for MDR1-2, an initial 94°C for 5 min; 40 cycles of 94°C
for 30 sec, 56°C for 1 min and 72°C for 1 min 30 sec; and
a final 10-min extension step at 72°C The PCR products
were loaded on a 1.5% agarose gel containing 0.5 μg/mL
ethidium bromide. Amplicons were purified using the
QIAquick 96 PCR BioRobot Kit and an automated
protocol on the BioRobot 8000 workstation (Qiagen,
Courtaboeuf, France). The purified fragments were se-
quenced using the BigDye Terminator v3.1 Cycle Sequen-
cing Kit (Applied Biosystems) using the primers described
above. The sequencing reaction products were purified
using the BigDye XTerminatorW Purification Kit (Applied
Biosystems) in accordance with the manufacturer's ins-
tructions. The purified products were sequenced using an
ABI Prism 3100 analyser (Applied Biosystems). Sequences
were analysed using Vector NTI advance(TM) software
(version 11, Invitrogen, Cergy Pontoise, France).
Pfdhfr SNP
A 562-bp fragment corresponding to the coding region of
Pfdhfr was amplified using the following primers: sense 5’-
ACG TTT TCG ATA TTT ATG C-3’ and antisense 5’
TCA CAT TCA TAT GTA CTA TTT ATT C-3’ [42]. The
reaction mixture contained 2.5 μl of genomic DNA, 2.5 μl
of 10X reaction buffer (Eurogentec), 0.5 μM each primer,
2.5 mM MgCl2, 200 μM deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Euromedex,
Souffelweyersheim, France) and 1 U of RedGoldStarW
DNA polymerase (Eurogentec) in a final volume of 25 μl.
The PCR conditions were as described in [42]. The ampli-
fied fragments were purified, sequenced (with the primers
used for PCR) and analysed as described above.Pfdhps SNP
A 672-bp fragment corresponding to the coding region
of Pfdhps was amplified using the following primers:
sense 50-GTT GAA CCT AAA CGT GCT GT-30 and
antisense 50-TTC ATC ATG TAA TTT TTG TTG TG-
30 [42]. The fragment was amplified as described for
pfdhfr, and the PCR conditions were as described in [42].
The amplified fragments were purified, sequenced (with
the primers used for PCR) and analysed as described
above.
Copy number of Pfmdr1
The Pfmdr1 copy number was estimated by TaqMan
real-time PCR (7900HT Fast Real-Time PCR system,
Applied Biosystems, Courtaboeuf, France) using the
single-copy gene β-tubulin (PF10_0084) as a reference.
The following previously reported oligonucleotide pri-
mers and probes were used with slight modifications
[12]: 5’-TGC ATC TAT AAA ACG ATC AGA CAA A-
3’, 5’-TCG TGT GTT CCA TGT GAC TGT-3’ and 5’-
VIC- TTT AAT AAC CCT GAT CGA AAT GGA ACC
TTT G-TAMRA-3’ for Pfmdr1 and 5’- TGA TGT GCG
CAA GTG ATC C-3’, 5’-TCC TTT GTG GAC ATT
CTT CCT C-3’ and 5’-FAM- TAG CAC ATG CCG TTA
AAT ATC TTC CAT GTC T-TAMRA-3’ for β-tubulin
(Eurogentec, Angers, France). Individual PCR reactions
were carried out using 1X TaqMan Universal PCR
Master Mix (Applied Biosystems), 900 nM forward pri-
mer, 900 nM reverse primer, 250 nM Taqman probe and
5 μl of template DNA in a final volume of 25 μl. The reac-
tion mixtures were prepared at 4°C in a 96-well optical re-
action plate (Applied Biosystems) covered with optical
adhesive covers (Applied Biosystems). The thermal cycling
conditions were 50°C for 2 min, 95°C for 10 min, and 50
cycles of 95°C for 15 s and 60°C for 1 min. Each sample
was assayed in triplicate, and the data were analysed with
SDS software 2.2.1 (Applied Biosystems). The PCR effi-
ciencies of all primer pairs were evaluated using a dilution
series of P. falciparum 3D7 genomic DNA and were found
to be sufficiently close to obviate the need for any correc-
tion factor. Therefore, the 2-ΔΔCt method of relative quan-
tification was used and adapted to estimate the copy
number of the pfmdr1 gene, where ΔΔCt= (Ctpfmdr1 - Ctβ-
tubuline)sample - (Ctpfmdr1 - Ctβ-tubuline)calibrator. Genomic
DNA extracted from the P. falciparum 3D7 strain, which
has a single copy of each gene, was used as a calibrator,
and β-tubulin served as the control housekeeping gene in
all experiments.
Results
One hundred and eighty-eight patients were recruited
for the study at the Hôpital Principal de Dakar. Gene
polymorphisms were evaluated in 174 isolates that were
slide-positive for P. falciparum.
Table 2 Number (no) and frequency (%) of the Pdhfr
mutations (codons 108, 51, 59, 16, and 164)
Codon No Wild type
no (%)
Mutated
no (%)
Wild type/
Mutated no (%)
S108N/T* 170 21 (12.4) 140* (82.4) 9 (5.2)
N51I 170 27 (15.9) 142 (83.5) 1 (0.6)
C59R 170 25 (14.7) 126 (74.1) 19 (11.2)
A16V 158 155 (98.1) 2 (1.3) 1 (0.6)
I164L 170 169 (99.4) 1 (0.6) 0 (0)
*One was 108T.
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tive samples. At the Pcrt gene, the codon 76 (K76T) mu-
tation was identified in 37.2% of the samples. One
sample (0.6%) was mixed, yielding both K76 and 76T.
The results for Pfmdr1 polymorphisms are shown in
Table 1. The codon 86 (N86Y) mutation was identified
in 16.6% of the tested samples. One isolate (0.6%) was
mixed, yielding both N86 and 86Y. A mutation in codon
184 (Y184F) was identified in 67.6% of the isolates.
Twenty-eight of the 29 isolates with the 86Y mutation
were also mutated at codon 184 (184F). No new SNP
was detected in Pfmdr1 gene. Only one isolate (0.6%)
harboured two copies of pfmdr1.
The results for Pfdhfr polymorphisms are presented in
Table 2. There was a mutation in 82.4% of the samples
for codon 108 (S108N/T) (only 1/140 S108N/T was
S108T), in 83.5% for codon 51 (N51I) and in 74.1% for
codon 59 (C59R). Nine samples (5.2%), one sample
(0.6%) and 19 samples (11.2%) were mixed, yielding both
S108 and 108N, N51 and 51I, and C59 and 59R, respect-
ively. The double mutant (108N and 51I) was detected
in 83.5% of the isolates, and the triple mutant (108N, 51I
and 59R) was detected in 75.3%. Two mutants were
detected for codon 16 (A16V).
The results for Pfdhps polymorphisms are presented in
Table 3. There was a mutation in 40.2% of the samples for
codon 437 (A437G), in 35.1% for codon 436 (S436F/A)
and in 1.8% for codon 613 (A613S). No mutant was
detected for codons 540 and 581.
There was no double mutant (437G and 540E) and no
quintuple mutant (Pfdhfr 108N, 51I and 59R and Pfdhps
437G and 540E). The prevalence of the quadruple mutant
(Pfdhfr 108N, 51I and 59R and Pfdhps 437G) was 36.5%.
Discussion
In response to increasing chloroquine resistance, Senegal
in 2004 switched to sulphadoxine-pyrimethamine with
amodiaquine as the first-line therapy. In 2006, artemether-
lumefantrine and artesunate-amodiaquine were the forms
of artemisinin-based combination therapy (ACT) recom-
mended by the WHO as the first-line anti-malarial regi-
men for managing uncomplicated malaria.Table 1 Number (no) and frequency (%) of the Pfmdr1
mutations (codons 86, 184, 1034, 1042, and 1246)
Codon No Wild type
no (%)
Mutated
no (%)
Wild type/
Mutated no (%)
N86Y 174 144 (82.8) 29 (16.6) 1 (0.6)
Y184F 173 56 (32.4) 117 (67.6) 0 (0)
S1034C 163 163 (100) 0 (0) 0 (0)
N1042D 170 170 (100) 0 (0) 0 (0)
D1246Y 168 168 (100) 0 (0) 0 (0)Mutations in Pfcrt have been shown to be correlated
with chloroquine resistance in different parts of the world
[43]. The prevalence of the Pfcrt 76T mutation decreased
since 2004 in Dakar. In 2000–2001 in Guediawaye, a sub-
urb of Dakar, a prevalence of 92% of 76T was observed in
pregnant women with malaria [44]. In Pikine, another
suburb of Dakar, the prevalence of 76T was 79% in 2000
[45], 63.9% in 2001 [46] and 59.5% in 2004 [47]. In 2002,
the prevalences of in vitro resistance to chloroquine and
of Pfcrt 76T mutation were 52% and 65%, respectively, in
patients hospitalized for malaria at the Hôpital Principal
de Dakar [48]. In 2001–2002, the prevalence of the pfcrt
76T mutation was 75.8% in pregnant women taking
chloroquine prophylaxis in Thiadiaye (84 km southeast of
Dakar) [49]. In Dielmo (280 km southeast of Dakar), the
in vitro resistance to chloroquine regularly increased from
32% in 1995 to 55% in 1999 [50-53].
In this study, the Pfcrt 76T mutation was identified in
37.2% of the patients recruited from October 2009 to
January 2010 in the Hôpital Principal de Dakar. These
data are consistent with previous works on molecular re-
sistance and on in vitro or ex vivo susceptibility in Dakar
in 2009 (22% of isolates exhibiting chloroquine resistance)
[54] and in Thies in 2007 (23% of isolates exhibiting
chloroquine resistance) [55].
This decrease in chloroquine resistance parallels the
withdrawal of chloroquine treatment and the introduc-
tion of ACT in 2002 in Senegal. However, in 2003,
chloroquine was still being administered to patients. The
prevalence of chloroquine in the urine ranged fromTable 3 Number (no) and frequency (%) of the Pfdhps
mutations (codons 437, 436, 540, 581, and 613)
Codon No Wild type
no (%)
Mutated
no (%)
Wild type/
Mutated no (%)
A437G 174 104 (59.8) 70 (40.2) 0 (0)
S436F/A 174 112 (64.3) 61 (35.1) 1 (0.6)
K540E 174 174 (100) 0 (0) 0 (0)
A581G 174 174 (100) 0 (0) 0 (0)
A613S 171 168 (98.2) 3 (1.8) 0 (0)
Wurtz et al. Malaria Journal 2012, 11:197 Page 6 of 10
http://www.malariajournal.com/content/11/1/19714.5% to 47.5% in two- to nine-year-old children from
northern Senegal and from 9.0% to 21.4% in children from
southern Senegal [56]. In 2006, Senegal reported 10.6%
chloroquine use and 9.7% ACT use [57]. Since 2006, more
than 1.5 million ACT treatments have been administered
in Senegal [3], and 184,170 doses of ACT were dispensed
in 2009 [4]. A reduction in chloroquine resistance was also
reported in Malawi after the withdrawal of chloroquine
treatment [58]. This observation prompted an in vivo
chloroquine study in Malawi five years later, in which
chloroquine was found to be 99% effective [59]. The rapid
dissemination of chloroquine resistance in Dielmo, despite
strictly controlled anti-malarial drug use, argues against
the re-introduction of chloroquine at least in mono-
therapy in places where the resistant allele has dropped to
very low levels following the discontinuation of chloro-
quine treatment [60]. It took 407 chloroquine treatments
(1.6 treatment courses/person/year) in the community to
raise the prevalence of the Pfcrt 76T mutation from an 8-
9% during the first year of re-introduction of chloroquine
(1993–1994) to 46% in 1995. Increased selective pressure
(2752 treatments during the period 1995–1999) did not
increase the prevalence of Pfcrt 76T or increased the
in vitro resistance to chloroquine, but this increased se-
lective pressure increased the incidence of clinical malaria
for patients within seven days of chloroquine treatment
from 2.6% in 1995 to 13% in 1999.
The Pfdhfr 108N mutation has been shown to be corre-
lated with in vitro and in vivo resistance to pyrimethamine
[10,17]. The OR for sulphadoxine-pyrimethamine failure
associated with Ser108Asn was 3.5 (95%CI: 1.9-6.3, meta-
analysis of 10 studies) for a 28-day follow-up [17]. The
additional mutations Asn51Ile, Cys59Arg or Ile164Leu
increase the level of in vitro resistance to anti-folate drugs
and sulphadoxine-pyrimethamine. The OR for codon 51
and 59 single mutants were 1.7 (95%CI: 1.0-3.0) and 1.9
(95%CI: 1.4-2.6), respectively [17]. In 2009, the prevalence
of Pfdhfr 108N was 82.4% in patients with malaria who
were treated at the Hôpital Principal de Dakar. The triple
mutation (51+59+108) increases the risk of in vivo resist-
ance to sulphadoxine-pyrimethamine by 4.3 (95%CI:
3.0-6.3, meta-analysis of 22 28-day studies). Isolates carry-
ing a combination of three mutations (108N, 51I and 59R)
associated with high-level pyrimethamine resistance
represented 75.3%. In 2002, in the same hospital, the
prevalence of Pfdhfr 108N was 65%, and triple mutants
were identified in 50% of the isolates [48]. In 2003, the
prevalence of mutations in Pfdhfr codon 108 was 78% in
Pikine, and the prevalence of the triple mutant was 61%
[61]. In 2007 in Keur Soce, a rural area, triple mutant was
identified in 67% of patients treated with sulphadoxine-
pyrimethamine combined with amodiaquine [8].
The Pfdhps 437G mutation has been shown to be corre-
lated with in vitro and in vivo resistance to sulphadoxine[11,17]. The single mutation Ala437Gly and the double
mutation Ala437Gly+Lys540Glu increase the risk of
in vivo resistance to sulphadoxine-pyrimethamine by 1.5
(95%CI: 1.0-2.4, meta-analysis of 12 studies) and 3.9 (95%
CI: 2.6-5.8, meta-analysis of 10 studies), respectively [17].
In 2009, the prevalence of the Pfdhps 437G mutation was
40.4% in patients with malaria who were treated at the
Hôpital Principal de Dakar. However, there was no isolate
carrying the double mutation (437G and 540E) that is
associated with high-level sulphadoxine resistance. The
mutation of codon 613 (A613S) (1.8%) was very rare in
Africa. In 2002, in the same hospital, only 20% of isolates
harboured the Pfdhps 437G mutation [48]. In 2003, the
mutation rate in Pfdhps codon 437G was 40% in Pikine
[61]. Several studies from 2006 to 2008 in Senegal showed
that the prevalence of Pfdhps 437G significantly increased
after intermittent preventive treatment of infants with
sulphadoxine-pyrimethamine [8,62]. Given the prevalences
of the triple and quadruple mutants in the population of
Dakar (75.3% Pfdhfr 108N, 51I and 59R triple mutant and
36.5% quadruple mutant Pfdhfr 108N, 51I and 59R and
Pfdhps 437G), the use of sulphadoxine-pyrimethamine
as an intermittent preventive treatment must be mon-
itored. Encouragingly, no quintuple mutant (Pfdhfr 108N,
51I and 59R and Pfdhps 437G and 540E), which is asso-
ciated with high-level sulphadoxine-pyrimethamine resist-
ance, has been identified to date. However, the single use
of sulphadoxine-pyrimethamine as seasonal IPT must be
inadvisable: sulphadoxine-pyrimethamine must be asso-
ciated with amodiaquine, artesunate or piperaquine for in-
stance [7,8].
Only one isolate (0.6%) had two copies of Pfmdr1. In
Asia, amplification of Pfmdr1 is associated with meflo-
quine resistance in vitro and in vivo [12,29,63]. The role of
increased copy number in mefloquine resistance in Africa
remains controversial. Isolates with a duplicated Pfmdr1
gene circulate in West Africa but are relatively rare [64].
Only one published clinical failure for mefloquine in West
Africa was found to be associated with in vitro resistance
and amplification of Pfmdr1 [65]. In addition, amodia-
quine resistance is not related to the amplification of
Pfmdr1 [66]. The role of the amplification of Pfmdr1 in
resistance to artemether-lumefantrine in Africa is still
debated. It seems that no Pfmdr1 gene amplification was
associated with artemether-lumefantrine failures in Africa
[67], whereas a copy number ≥4 is associated with reduced
in vitro susceptibility to lumefantrine [68]. In 2009, in
Dakar, only 1% of the isolates presented reduced in vitro
susceptibility to lumefantrine [44], and this prevalence
did not increase in Senegal after the introduction of
ACT. In 1996, 6% of isolates from Dielmo were resistant
in vitro to lumefantrine [69]. In recent years, the efficacy
of artemether-lumefantrine in several trials in Senegal has
ranged from 96 to 100% [70-72].
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184F were 16.6% and 67.6%, respectively. No isolate car-
ried a mutation in codons 1034, 1042 or 1246. In 2000
and 2001, prevalences of 31% and 30.6 were observed
for Pfmdr1 86Y in Pikine [45,46]. The role of poly-
morphism in Pfmdr1 is still debated. Point mutations in
Pfmdr1, most notably at codon 86, have been found to
be associated with decreased chloroquine susceptibility
[73]. Nevertheless, this association is not a consistent
finding [24]. The Pfmdr1 86Y mutation also has been
found to be associated with increased susceptibility to
mefloquine or artemisinin [29-31]. This association, too,
is not a consistent finding [63]. In addition, no clear
association between the Pfmdr1 184F mutation and mef-
loquine failure has been established, although this allele
is widespread in Cambodia [74]. The Pfmdr1 86Y muta-
tion has also been shown to be associated with in vivo
resistance to amodiaquine in recrudescence after mono-
therapy with amodiaquine [75] or after combination
therapy with artesunate-amodiaquine [76]. The Pfmdr1
1246Y mutation has also been found to be associated
with in vitro resistance to amodiaquine [77] and with
recrudescent infection after treatment with amodiaquine
or amodiaquine-artesunate [76,78]. In a meta-analysis,
the Pfmdr1 86Y mutation was demonstrated to be asso-
ciated with amodiaquine failure, with an odds ratio of
5.4 [17]. Based on this hypothesis, the 16.6% prevalence
of Pfmdr1 of 86Y predicts that 16.6% of isolates would be
resistant to amodiaquine in 2009 in Senegal. In 2009, in
Dakar, only 6% of isolates showed in vitro reduced suscep-
tibility to monodesethylamodiaquine, the active metabolite
of amodiaquine [54]. The resistance to amodiaquine has
remained low even after the introduction of artesunate-
amodiaquine in 2006 in Senegal relative to the resistance
prevalences of Dielmo in 1996 and 1999 (0%) [50,79] and
Mlomp in Casamance, south-western Senegal, in 2004
(5%) [80]. The artesunate-amodiaquine–associated cure
rates were >99.3% in Mlomp and Keur-Socé when adminis-
tered either as a single daily dose or two daily doses [81].
The fixed-dose combination of artesunate-amodiaquine
(ASAQ) exhibits a cure rate >98.5% [82]. The cure rates
were 100% in the populations experiencing a second or
third episode of uncomplicated malaria following treatment
with ASAQ [69]. However, ACT efficacy and resistance
must be monitored because the first clinical failures, or at
least extended parasite clearance times, have been
described in Cambodia [38,83]. In this context, it is import-
ant to implement in vitro and in vivo surveillance pro-
grammes, such as those championed by the Worldwide
Antimalarial Resistance Network [84,85].
Since 2004, the prevalence of chloroquine resistance has
decreased, but the data argue against the re-introduction
of chloroquine at least in mono-therapy in places where
the resistant allele has dropped to very low levels followingdiscontinuation of chloroquine treatment. The prevalence
of isolates resistant to pyrimethamine is high (82.4%), with
75.3% of parasites exhibiting high-level pyrimethamine
resistance. The prevalence of isolates resistant to sulpha-
doxine was 40.2%. However, no quintuple mutant (Pfdhfr
108N, 51I and 59R and Pfdhps 437G and 540E), which is
associated with high-level sulphadoxine-pyrimethamine
resistance, has been identified to date. The resistance to
amodiaquine remains moderate. Intensive surveillance of
P. falciparum susceptibility to anti-malarial drugs must
be conducted regularly in Senegal. However, maximiz-
ing the efficacy and longevity of ACT as a tool to control
malaria will critically depend on pursuing intensive re-
search into identifying in vitro markers as well as imple-
menting in vitro and in vivo surveillance programs. In this
context, there is a need to identify molecular markers that
predict ACT resistance which can provide an active sur-
veillance method to monitor temporal trends in parasite
susceptibility.
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